Abstract
Ebola DNA vaccine is incorporated into PLGA-PLL/γPGA nanoparticles and administered to skin using a microneedle (MN) patch. The nanoparticle delivery system increases vaccine thermostability and immunogenicity compared to free vaccine. Vaccination by MN patch produces stronger immune responses than intramuscular administration.
Keywords:
Ebola DNA vaccine; cationic nanoparticles; indradermal vaccine delivery; microneedle patch; minimally invasive skin vaccination.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
MeSH terms
-
Animals
-
Ebola Vaccines* / chemistry
-
Ebola Vaccines* / pharmacology
-
HeLa Cells
-
Humans
-
Immunogenicity, Vaccine
-
Lactic Acid* / chemistry
-
Lactic Acid* / pharmacology
-
Mice
-
Nanoparticles* / chemistry
-
Nanoparticles* / therapeutic use
-
Needles
-
Polyglutamic Acid* / chemistry
-
Polyglutamic Acid* / pharmacology
-
Polyglycolic Acid* / chemistry
-
Polyglycolic Acid* / pharmacology
-
Polylactic Acid-Polyglycolic Acid Copolymer
-
Polylysine* / chemistry
-
Polylysine* / pharmacology
-
Vaccines, DNA* / chemistry
-
Vaccines, DNA* / pharmacology
Substances
-
Ebola Vaccines
-
Vaccines, DNA
-
Polylactic Acid-Polyglycolic Acid Copolymer
-
Polylysine
-
Polyglutamic Acid
-
Polyglycolic Acid
-
Lactic Acid